Retatrutide 10 mg Single

Research Material

Retatrutide 10 mg Single

$30.00

In stock

Research identity: investigational triple-receptor agonist studied at GIPR, GLP-1R, and GCGR.

  • Phase 2 human research record
  • Active phase 3 registry context
  • Mechanism map, evidence limits, and primary sources below

Catalog scope: 10 mg is the listed material strength—not a dose, schedule, or use instruction. This listing is not an FDA-approved drug product. For laboratory research only; not for human or veterinary use.

COMPOUND DOSSIER Read identity, mechanism, evidence, limits, and sources
Catalog sourceResearch Here
Request methodEmail review
Research recordFull dossier below

BUILD ONE COMPLETE LIST

Need more than one item?

Add this item, keep browsing, and add every product or option you need. Your list stays saved in this browser until you send one complete email request or remove it.

  1. 1Choose an in-stock or available-for-request option and quantity.
  2. 2Add it to your request list and continue shopping.
  3. 3Review the full list and send one email request.

RESEARCH HERE · COMPOUND DOSSIER

The record behind the shelf.

Plain-language identity, mechanism, evidence maturity, study endpoints, limitations, and direct source records—organized for careful reading, never copied from a dosing site.

PHASE 2 HUMAN EVIDENCEINVESTIGATIONAL

TRIPLE-RECEPTOR LIGAND

Retatrutide

A clinical-stage peptide designed to activate three metabolic hormone receptors. Published trials examine defined metabolic and liver-related endpoints under protocol-controlled conditions.

GIPRGLP-1RGCGR
Development code
LY3437943
Strongest indexed evidence
Randomized phase 2 human study
Current status
Investigational; phase 3 program listed
Evidence lanes
Metabolic outcomes · liver-fat imaging · safety

01

What it is

Retatrutide is described in the clinical literature as a single peptide agonist at the glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon receptors.

Read carefully: receptor activity is a molecular description—not proof of a clinical result for an unverified vial.

02

What researchers measured

  • Prespecified change in body weight over time
  • Cardiometabolic measures collected in a controlled trial
  • Liver-fat change in a nested phase 2a analysis
  • Adverse events, discontinuations, and protocol tolerability

03

What the record does not prove

  • That a catalog vial is the same material used in a clinical trial
  • That one study population predicts another
  • That a stated milligram amount confirms identity, purity, sterility, or fill accuracy
  • That an investigational program is an FDA approval

EVIDENCE SNAPSHOT

Three records, three different questions.

Open the source itself before repeating a result. The study design—not the headline—defines what can be concluded.

2023 · PHASE 2Triple-Hormone-Receptor Agonist Retatrutide for Obesity

Randomized human study; 338 adults; 48-week weight and safety endpoints.

PMID 37366315 ↗ 2024 · PHASE 2ARetatrutide and metabolic dysfunction-associated steatotic liver disease

Nested human analysis focused on liver-fat measurements within a defined trial.

PMID 38858523 ↗ ACTIVE REGISTRYTRIUMPH phase 3 master protocol

Current trial-registry context for an investigational development program.

NCT05929066 ↗

DETAILED COMPOUND GUIDE

The fuller record—not a one-paragraph summary.

This section covers the same questions people look for on large peptide-reference sites, while separating published findings from marketing claims and catalog material.

01Reported research findings+

In the 338-participant phase 2 obesity trial, mean body-weight change at 48 weeks ranged from −8.7% in the lowest studied group to −24.2% in the highest studied group, compared with −2.1% for placebo. The publication also reported categorical 5%, 10%, and 15% weight-reduction endpoints.

A separate phase 2 diabetes study evaluated HbA1c and body-weight outcomes, while a nested phase 2a analysis evaluated liver-fat measurements.

Scope: these are clinical-trial results for sponsor-controlled study material—not a promised result or quality claim for this catalog listing.

02How the three signals differ+
  • GLP-1 receptor: involved in glucose-dependent insulin signaling, appetite, and gastric-emptying pathways.
  • GIP receptor: another incretin pathway involved in nutrient-responsive metabolic signaling.
  • Glucagon receptor: involved in hepatic energy and glucose signaling; this third target distinguishes retatrutide from dual agonists.

Activating three receptors does not mean every effect is additive or beneficial. Trial design and safety monitoring remain essential.

03Side effects and risk signals+

The phase 2 publication reported gastrointestinal events as the most common adverse events. They were dose-related and mostly mild to moderate; nausea, diarrhea, vomiting, and constipation appear in the published clinical record.

Dose-dependent heart-rate increases peaked around week 24 and declined afterward in the trial. Retatrutide remains investigational, so it does not have an FDA-approved prescribing label that establishes a complete contraindication or interaction list.

Public guide sites also list dehydration, gallbladder problems, pancreatitis, severe allergic reaction, bowel obstruction, and delayed gastric emptying. Those items should be treated as risk-screening topics—not as proof that each occurred at a defined rate in the cited retatrutide trial.

04Contraindications and interactions+

No FDA-approved retatrutide contraindication section exists. Trial eligibility criteria and medical monitoring cannot be converted into a universal self-use checklist.

No controlled evidence was found validating the commercial “stacking” combinations promoted on guide sites. Combining metabolic, glucose-lowering, appetite, or gastric-motility agents can change risk and requires qualified clinical review.

05Protocol and handling context+

The published phase 2 programs used protocol-controlled once-weekly administration, prespecified escalation groups, eligibility rules, adverse-event monitoring, and sponsor-manufactured study material.

That context belongs in the research record. It is not a reconstitution recipe for a third-party vial. Exact solvent compatibility, concentration, stability, sterility, endotoxin status, and storage after preparation require material-specific validated documentation.

06Claim audit+

SUPPORTED IN PHASE 2 HUMAN RESEARCHBody-weight, glycemic, cardiometabolic, liver-fat, and tolerability endpoints

MECHANISTIC CONTEXTTriple GIPR / GLP-1R / GCGR agonism

NOT ESTABLISHED FOR THIS VIALClinical equivalence, treatment outcome, safety, sterility, or dosing suitability

NOT VALIDATEDInternet stacking plans and self-directed reconstitution schedules

REFERENCE DESK

Every major claim, sorted by evidence.

The popular-guide information is retained here, but labeled so a reader can tell a clinical result from a theory, extrapolation, or unsupported sales claim.

BENEFITS & APPLICATIONS INDEX

What public guides claim

HUMAN PHASE 2Body-weight reduction, glycemic change, cardiometabolic measures, and liver-fat endpoints

EMERGINGBlood-pressure, lipid, vascular, sleep-apnea, and other metabolic-risk applications under study

NOT ESTABLISHEDAutoimmune relief, collagen production, skin tightening, wound healing, angiogenesis, muscle regeneration, addiction, depression, or lifespan extension

INTERACTIONS & CAUTIONS INDEX

Topics a full guide should name

  • Other GLP-1/GIP/glucagon-pathway agents
  • Insulin, sulfonylureas, glinides, and other glucose-lowering agents
  • Oral medicines whose absorption may be affected by delayed gastric emptying
  • History of pancreatitis, gallbladder disease, severe gastric-motility problems, kidney or liver disease
  • Pregnancy, breastfeeding, hypersensitivity, and thyroid-tumor history are frequently listed by commercial guides

Retatrutide has no approved label defining a complete interaction or contraindication list. These are screening topics, not a validated checklist.

STACKING CLAIMS INDEX

Named on commercial pages

AOD-9604BPC-157TB-500GHK-CuSemaxSelankGlutathioneLIPO-C

Guide sites associate these pairings with plateaus, muscle preservation, tissue recovery, skin changes, mood, liver support, or energy. No controlled trial establishes those combined outcomes or safety with retatrutide.

STORAGE & HANDLING

What can be stated responsibly

  • Protect peptide material from uncontrolled heat, light, moisture, and repeated temperature changes.
  • Do not infer stability from a generic peptide-storage chart.
  • Require batch-specific solvent compatibility, concentration, temperature, light, freeze/thaw, and post-preparation stability data.
  • Purity, sterility, endotoxin, fill mass, and stability are separate quality questions.
Is retatrutide FDA approved?+

No. It remains investigational. ClinicalTrials.gov lists ongoing development studies.

How is it different from tirzepatide?+

Retatrutide targets GIP, GLP-1, and glucagon receptors; tirzepatide targets GIP and GLP-1 receptors. Results from different trials cannot be treated as a direct head-to-head comparison.

Does a “10 mg” vial mean a 10 mg dose?+

No. It is a catalog strength claim. It does not establish dose, concentration after preparation, accuracy, identity, or suitability.

Why are internet unit charts not reproduced here?+

They combine an assumed vial content, solvent volume, syringe scale, and human-use schedule. None of those assumptions is validated for a third-party research vial by the cited clinical trials.

REFERENCE LAYERPrimary and authoritative sources shown above control the evidence classification. Reported-practice notes are retained without public vendor attribution.
IDENTITY CHECK

What must match?

Name, exact sequence, chemical modifications, counterion or salt form, lot, test method, and the material described by each source.

QUALITY CHECK

What does a COA answer?

A report may address selected attributes for a stated sample and method. Purity alone does not establish identity, sterility, endotoxin level, or fill amount.

CATALOG CHECK

What does “10 mg” mean here?

It is the catalog strength label for the listed material. It is not a protocol, dose, schedule, or clinical recommendation.

SOURCE SHELF

Keep reading from primary records.